Potent, selective mGlu8a agonist (EC50 = 31 nM). Displays > 100-fold selectivity over mGlu1-7 and displays little or no activity at NMDA and kainate receptors. Increases c-Fos expression in stress-related brain areas following systemic administration in mice in vivo. Also potent anticonvulsant in mice in vivo. Caged (S)-3,4-DCPG (Cat. No. 3330), (RS)-3,4-DCPG (Cat. No. 1394) and (R)-3,4-DCPG (Cat. No. 1395) also available.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|phosphate buffered saline||23.92||100|
Preparing Stock Solutions
The following data is based on the product molecular weight 239.18. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.18 mL||20.9 mL||41.81 mL|
|5 mM||0.84 mL||4.18 mL||8.36 mL|
|10 mM||0.42 mL||2.09 mL||4.18 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Linden et al (2003) Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology 45 473 PMID: 12907308
Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732 PMID: 11311902
Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111 PMID: 9455991
Thomas et al (2001) (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 40 311 PMID: 11166323
If you know of a relevant reference for (S)-3,4-DCPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Potent selective mGlu8a agonists Group III Receptors mGlu8R Glutamate Metabotropic UBP1109 UBP 1109 Glutamate (Metabotropic) Group III Receptors
1 Citation for (S)-3,4-DCPG
Citations are publications that use Tocris products. Selected citations for (S)-3,4-DCPG include:
Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638
Do you know of a great paper that uses (S)-3,4-DCPG from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.